Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MNMD vs CMPS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MNMD Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 5–0 Matrix Metrics)

MNMD Overall Winner 6-Pillar Tally: MNMD 4 – 0 CMPS (2 Tie) Matrix Metrics: MNMD 5 – 0 CMPS

As of Nov 16, 2026, Mind Medicine (MindMed) Inc. Common Shares (MNMD) is the stronger overall head-to-head candidate over COMPASS Pathways Plc American Depository Shares (CMPS) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MNMD carries a Unified Composite Score of 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin), whereas CMPS carries 57.3/100 (HOLD) at $8.30 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: MNMD trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 65.3); meanwhile CMPS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MNMD vs CMPS
MNMD NASDAQ Head-to-Head Winner
Mind Medicine (MindMed) Inc. Common Shares
Medicinal Chemicals & Botanical Products
$15.02
+1.01% 1D
Market Cap $1.4B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.79β · 55% Vol
Unified Composite Score
63.1 / 100 BUY
Tech 75.0 Fund 62.0 Flow 60.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 65
RSI-14: 65.3 · SMA20: $13.52 · SMA50: $12.57
CMPS NASDAQ
COMPASS Pathways Plc American Depository Shares
Pharmaceutical Preparations
$8.30
-7.88% 1D
Market Cap $1.3B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.84β · 122% Vol
Unified Composite Score
57.3 / 100 HOLD
Tech 65.0 Fund 60.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.1%), weak momentum, RSI 34
RSI-14: 33.9 · SMA20: $10.08 · SMA50: $11.79

6-Pillar Scorecard Institutional Category Breakdown (MNMD 4 – 0 CMPS)

Columns: Metric · MNMD · CMPS
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale MNMD
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $1.4B $1.3B
3. Profitability & Quality MNMD
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -85.6% -296.4%
4. Balance Sheet & Cash Flow MNMD
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.70 Book/Sh · -85.6% ROE $1.00 Book/Sh · -296.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MNMD
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 70.7% (6th %ile) 80.6% (16th %ile)
Put/Call OI Skew 0.18x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MNMD (5) vs CMPS (0)
Institutional Metric MNMD CMPS Criterion Row Edge
Market Capitalization
Scale
$1.4B $1.3B Larger Scale MNMD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-85.6% -296.4% Higher ROE MNMD
52-Week Range Position
Momentum
98% ($5–$15) 31% ($5–$16) Stronger Trend MNMD
Beta / 30D Volatility
Risk Regime
1.79β · 55% Vol 1.84β · 122% Vol Lower Realized Risk MNMD
Unified Institutional Score
Composite Signal
63.1 / 100 (BUY) 57.3 / 100 (HOLD) Higher Composite MNMD
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.70 Book/Sh · -85.6% ROE) N/A ($1.00 Book/Sh · -296.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MNMD +6.25 pp
MNMD: +19.54% · CMPS: +13.29%
3M Horizon CMPS +15.08 pp
MNMD: +29.15% · CMPS: +44.23%
6M Horizon CMPS +15.08 pp
MNMD: +29.15% · CMPS: +44.23%
1Y Horizon CMPS +15.08 pp
MNMD: +29.15% · CMPS: +44.23%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MNMD vs CMPS. Trailing 12-month operating profitability (MNMD 0.0% vs CMPS 0.0%) and valuation multiples (MNMD N/M vs CMPS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MNMD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.6% · N/M
CMPS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-296.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MNMD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 70.7%
IV Percentile 6th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MNMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CMPS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 80.6%
IV Percentile 16th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CMPS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MNMD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CMPS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $1.3B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MNMD vs CMPS Key Questions & Quantitative Answers

As of Nov 16, 2026, Mind Medicine (MindMed) Inc. Common Shares (MNMD) is the stronger overall head-to-head candidate over COMPASS Pathways Plc American Depository Shares (CMPS) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MNMD carries a Unified Composite Score of 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin), whereas CMPS carries 57.3/100 (HOLD) at $8.30 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: MNMD trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 65.3); meanwhile CMPS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MNMD leads the Growth & Scale pillar: MNMD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CMPS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MNMD generates N/A in USD-normalized revenue versus N/A for CMPS. In operating R&D and SG&A reinvestment, MNMD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CMPS.

MNMD and CMPS trade at balanced relative valuation multiples. MNMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CMPS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MNMD (-85.6% ROE) versus CMPS (-296.4% ROE) capital efficiency.

In options market volatility and institutional positioning, MNMD carries 70.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.79β · 55% Vol realized risk). By comparison, CMPS carries 80.6% implied volatility (16th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.84β · 122% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.